Advertisement

Diagnosis and Management of Sexual Pain Disorders: Dyspareunia

  • Jill M. Krapf
  • Andrew T. GoldsteinEmail author

Abstract

Dyspareunia can be one of the most challenging complaints that providers encounter in the office setting. Ensuring adequate time and a comfortable setting to address a woman’s concerns is essential to evaluation and treatment. Understanding the broad differential diagnosis of painful intercourse guides history taking. A thorough, yet focused, pelvic examination is necessary to determine the cause of the sexual pain. Identifying the location of the pain is the first step in determining the diagnosis. Although specific conditions may be associated with dyspareunia, sexual pain often falls into the category of vulvodynia or more specifically provoked vestibulodynia. Sexual pain can significantly affect a woman’s well-being and quality of life. Restoration of lasting and satisfying sexual function often requires a multidimensional understanding of the condition. Providers should feel empowered to treat this condition with the information reviewed in this chapter.

Keywords

Diagnosis Management Sexual pain disorder Dyspareunia 

Supplementary material

References

  1. 1.
    Latthe P, Latthe M, Say L, Gulmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health. 2006;6:177–83.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Basson R, Leiblum S, Brotto L, et al. Definitions of women’s sexual dysfunction reconsidered: advocating expansion and revision. J Psychosom Obstet Gynaecol. 2003;24:221–9.CrossRefPubMedGoogle Scholar
  3. 3.
    APA. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.Google Scholar
  4. 4.
    Binik YM. The DSM diagnostic criteria for vaginismus. Arch Sex Behav. 2010;39:278–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Schultz WW, Basson R, Binik Y, et al. Women’s sexual pain and its management. J Sex Med. 2005;2:301–16.CrossRefGoogle Scholar
  6. 6.
    Moyal-Barracco M, Lynch PJ. 2003 ISVVD terminology and classification of vulvodynia: a historical perspective. J Reprod Med. 2004;49(10):772–7.PubMedGoogle Scholar
  7. 7.
    Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. Obstet Gynecol. 2009;113(5):1124–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc. 2003;58:82–8.PubMedGoogle Scholar
  9. 9.
    Perelman M. Psychosocial history. In: Goldstein I, Meston C, Davis S, Traish A, editors. Women’s sexual function and dysfunction: study, diagnosis and treatment. Abingdon: Taylor and Francis; 2005.Google Scholar
  10. 10.
    Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard operating procedures for taking a sexual history. J Sex Med. 2012. doi: 10.1111/j.1743-6109.2012.02823.x.PubMedGoogle Scholar
  11. 11.
    Perelman M. Combination therapy for sexual dysfunction: integrating sex therapy and pharmacotherapy. In: Balon R, Segraves R, editors. Handbook of sexual dysfunction. Boca Raton: Taylor and Francis; 2005. p. 13–41.Google Scholar
  12. 12.
    Bouchard C, Brisson J, Fortier M, et al. Use of oral contraceptive pills and vulvar vestibulitis: a case control study. Am J Epidemiol. 2002;156:254–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Greenstein A, Ben-Aroya Z, Fass O, et al. Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. J Sex Med. 2007;4:1679–83.CrossRefPubMedGoogle Scholar
  14. 14.
    Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, Goldstein I. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med. 2006;3(1):104.CrossRefPubMedGoogle Scholar
  15. 15.
    Clayton AH, Campbell BJ, Favit A, et al. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. J Clin Psychiatry. 2007;68:1860–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Ledger WJ, Monif GRG. A growing concern: inability to diagnose vulvovaginal infections correctly. Obstet Gynecol. 2004;130:782–4.CrossRefGoogle Scholar
  17. 17.
    Goldstein AT, Goldstein GR. Vulvar punch biopsy. J Sex Med. 2009;6(5):1214–7.CrossRefPubMedGoogle Scholar
  18. 18.
    King M, Rubin R, Goldstein A. Current uses of surgery for the treatment of genital pain. Curr Sex Health Rep. 2014;6(4):252–8.CrossRefGoogle Scholar
  19. 19.
    Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med. 2013;1:30–3.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Goldstein AT, Burrows L. Vulvodynia. J Sex med. 2008;5:5–15.CrossRefPubMedGoogle Scholar
  21. 21.
    Bohm-Starke N, Johannesson U, Hilliges M, Rylander E, Torebjork E. Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: a contributing factor in vulvar vestibulitis? J Reprod Med. 2004;49:888–92.PubMedGoogle Scholar
  22. 22.
    Harlow BL, Vitonis AF, Stewart EG. Influence of oral contraceptive use on the risk of adult-onset vulvodynia. J Reprod Med. 2008;53(2):102–10.PubMedGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. Ann Emerg Med. 2011;58(1):67–8.CrossRefGoogle Scholar
  24. 24.
    Reichman O, Sobel J. Desquamative inflammatory vaginitis. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1042–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Krapf JM, Goldstein A. The vulvar dermatoses. Female Patient. 2012;37(4):1–5.Google Scholar
  26. 26.
    Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Foster DC, Hasday JD. Elevated tissue levels of interleukin-1 beta and tumor necrosis factor-alpha in vulvar vestibulitis. Obstet Gynecol. 1997;89:291–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Gerber S, Witkin SS, Sucki D. Immunological and genetic characterization of women with vulvodynia. J Med Life. 2008;1:432–8.PubMedGoogle Scholar
  29. 29.
    Dede M, Yenen MC, Yilmaz A, Baser I. Successful treatment of persistent vulvodynia with submucous infiltration of betamethasone and lidocaine. Eur J Obstet Gynecol Reprod Biol. 2006;124(2):258–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Kamdar N, Fisher L, MacNeill C. Improvement in vulvar vestibulitis with montelukast. J Reprod Med. 2007;52(10):912–6.PubMedGoogle Scholar
  31. 31.
    Marinoff SC, Turner ML, Hirsch RP, Richard G. Intralesional alpha interferon: cost-effective therapy for vulvar vestibulitis syndrome. J Reprod Med. 1993;38(1):19–24.PubMedGoogle Scholar
  32. 32.
    Bohm-Starke N, Hilliges M, Falconer C, Rylander E. Increased intraepithelial innervations in women with vulvar vestibulitis syndrome. Gynecol Obstet Investig. 1998;46:256–60.CrossRefGoogle Scholar
  33. 33.
    Westrom LV, Willen R. Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet Gynecol. 1998;91:572–6.PubMedGoogle Scholar
  34. 34.
    Bohm-Starke N, Hilliges M, Falconer C, Rylander E. Neurochemical characterization of the vestibular nerves in women with vulvar vestibulitis syndrome. Gynecol Obstet Investig. 1999;48:270–5.CrossRefGoogle Scholar
  35. 35.
    Bornstein J, Goldschmid N, Sabo E. Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. Gynecol Obstet Investig. 2004;58:171–8.CrossRefGoogle Scholar
  36. 36.
    Bornstein J, Cohen Y, Zarfati D, Sela S, Ophir E. Involvement of heparanase in the pathogenesis of localized vulvodynia. Int J Gynecol Pathol. 2008;27:136–41.CrossRefPubMedGoogle Scholar
  37. 37.
    Zolnoun DA, Hartmann KE, Steege JF. Overnight 5 % lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003;102(1):84–7.PubMedGoogle Scholar
  38. 38.
    Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008;112(3):579–85.CrossRefPubMedGoogle Scholar
  39. 39.
    Steinberg AC, Oyama IA, Rejba AE, Kellogg-Spadt S, Whitmore KE. Capsaicin for the treatment of vulvar vestibulitis. Am J Obstet Gynecol. 2005;192(5):1549–53.CrossRefPubMedGoogle Scholar
  40. 40.
    Pagano R, Wong S. Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. J Low Genit Tract Dis. 2012;16(4):394–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Leo RJ, Dewani S. A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med. 2013;10:2497–505.CrossRefPubMedGoogle Scholar
  42. 42.
    Goldstein AT, Klingman D, Christopher K, Johnson C, Marinoff SC. Outcome assessment of vulvar vestibulectomy with vaginal advancement for vulvar vestibulitis syndrome: results of a post-operative questionnaire survey. J Sex Med. 2006;3(5):923–31.CrossRefPubMedGoogle Scholar
  43. 43.
    Goetsch MF. Simplified surgical revision of the vulvar vestibule for vulvar vestibulitis. Am J Obstet Gynecol. 1996;174(6):1701–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Tommola P, Unkila-Kallio L, Paavonen J. Surgical treatment of vulvar vestibulitis: a review. Acta Obstet Gynecol Scand. 2010;89(11):1385–95.CrossRefPubMedGoogle Scholar
  45. 45.
    Rosenbaum TY, Owens A. The role of pelvic floor physical therapy in the treatment of pelvic and genital pain-related sexual dysfunction (CME). J Sex Med. 2008;5(3):513–23.CrossRefPubMedGoogle Scholar
  46. 46.
    Hartmann D, Sarton J. Chronic pelvic floor dysfunction. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):977–90.CrossRefPubMedGoogle Scholar
  47. 47.
    Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, Fariello JY, Whitmore KE. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J. 2010;21(7):895–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013;19(5):288–92.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Rosenbaum TY. Pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: a literature review. J Sex Med. 2007 Jan;4(1):4–13.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyGeorge Washington University School of MedicineWashington, DCUSA
  2. 2.The George Washington University School of MedicineWashington, DCUSA

Personalised recommendations